An inhaled drug for the treatment of Parkinson’s disease has shown positive results in a Phase I clinical trial, US-based Civitas Therapeutics has announced.
The study showed that CVT-301, an inhaled formulation of levodopa (L-dopa) for the rapid relief from motor fluctuations, is safe and easily absorbed into the bloodstream, via the lungs, at levels that are likely to produce a therapeutic outcome.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Civitas plans to present comprehensive data from the Phase I study at a future scientific meeting.
Civitas co-founder and chief medical officer Martin Freed said that due to the unpredictability of oral L-dopa, the therapeutic rationale for using inhaled L-dopa to manage motor fluctuations in Parkinson’s disease was intuitive but, until now, technically impractical.
"The Phase I data demonstrated the transformative potential of CVT-301 to enable patients to better manage their motor symptoms in light of the extensive clinical experience correlating L-dopa plasma levels to symptomatic relief documented over the past 40 years," said Freed.
Civitas chief scientific officer Dr Richard Batycky added, "As expected, the tolerability of CVT-301 and L-dopa pharmacokinetic profile behaved consistently with the other molecules we have taken into the clinic over the last decade.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData"Our technology’s proven unique ability to deliver a large, precise dose with an immediate onset should enable Parkinson’s patients to abort ‘off’ episodes and thereby helping to avoid debilitating disruptions in their lives," he said.
Image caption: CVT-301 is able to be absorbed into the bloodstream via the lungs ( Image by Renjith Krishnan).
